19Jan 2022
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction

Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction

When and how to initiate sodium–glucose co‐transporter 2 (SGLT2) inhibitors. Data based on enrolment criteria of the DAPA‐HF, EMPEROR‐Reduced and EMPULSE trials. eGFR, estimated glomerular filtration rate; HFrEF, heart failure with reduced ejection fraction. Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have recently been recommended as a foundational therapy for patients with heart failure (HF) and reduced ejection fraction (HFrEF) because of their favourable effects on mortality, clinical events and quality of life. While clinical practice guidelines have recommended dapagliflozin or empagliflozin in all patients with HFrEF, or sotagliflozin in those with HFrEF and concomitant diabetes, the timing and practical integration of these drugs in clinical practice is less well defined...

  • #cardiology

Like

Save

Share